Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) - Net Assets
Based on the latest financial reports, Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) has net assets worth NT$3.21 Billion TWD (≈ $101.25 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.44 Billion ≈ $139.84 Million USD) and total liabilities (NT$1.23 Billion ≈ $38.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Chunghwa Chemical Synthesis & Biotech Co (1762) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.21 Billion |
| % of Total Assets | 72.4% |
| Annual Growth Rate | 9.06% |
| 5-Year Change | 34.35% |
| 10-Year Change | 80.11% |
| Growth Volatility | 14.27 |
Chunghwa Chemical Synthesis & Biotech Co Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Chunghwa Chemical Synthesis & Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Chunghwa Chemical Synthesis & Biotech Co for the complete picture of this company's asset base.
Annual Net Assets for Chunghwa Chemical Synthesis & Biotech Co Ltd (2008–2024)
The table below shows the annual net assets of Chunghwa Chemical Synthesis & Biotech Co Ltd from 2008 to 2024. For live valuation and market cap data, see how much is Chunghwa Chemical Synthesis & Biotech Co worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.36 Billion ≈ $105.76 Million |
+0.20% |
| 2023-12-31 | NT$3.35 Billion ≈ $105.55 Million |
+4.92% |
| 2022-12-31 | NT$3.19 Billion ≈ $100.60 Million |
+10.32% |
| 2021-12-31 | NT$2.89 Billion ≈ $91.19 Million |
+15.83% |
| 2020-12-31 | NT$2.50 Billion ≈ $78.72 Million |
+24.00% |
| 2019-12-31 | NT$2.02 Billion ≈ $63.49 Million |
+1.57% |
| 2018-12-31 | NT$1.98 Billion ≈ $62.50 Million |
+8.93% |
| 2017-12-31 | NT$1.82 Billion ≈ $57.38 Million |
+2.83% |
| 2016-12-31 | NT$1.77 Billion ≈ $55.80 Million |
-4.97% |
| 2015-12-31 | NT$1.86 Billion ≈ $58.72 Million |
+15.34% |
| 2014-12-31 | NT$1.62 Billion ≈ $50.91 Million |
-5.56% |
| 2013-12-31 | NT$1.71 Billion ≈ $53.91 Million |
+2.12% |
| 2012-12-31 | NT$1.68 Billion ≈ $52.79 Million |
-0.06% |
| 2011-12-31 | NT$1.68 Billion ≈ $52.82 Million |
-0.37% |
| 2010-12-31 | NT$1.68 Billion ≈ $53.01 Million |
+40.89% |
| 2009-12-31 | NT$1.19 Billion ≈ $37.63 Million |
+42.60% |
| 2008-12-31 | NT$837.53 Million ≈ $26.39 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chunghwa Chemical Synthesis & Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14553.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$1.72 Billion | 51.37% |
| Common Stock | NT$775.60 Million | 23.10% |
| Other Comprehensive Income | NT$523.28 Million | 15.59% |
| Other Components | NT$333.75 Million | 9.94% |
| Total Equity | NT$3.36 Billion | 100.00% |
Chunghwa Chemical Synthesis & Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Chunghwa Chemical Synthesis & Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Crown Seal Public Company Limited
BK:CSC
|
$68.48 Million |
|
Ihlas Holding AS
IS:IHLAS
|
$68.49 Million |
|
Foodnamoo. Inc
KQ:290720
|
$68.50 Million |
|
Astra Exploration Inc
V:ASTR
|
$68.53 Million |
|
Apex Science & Engineering Corp
TW:3052
|
$68.44 Million |
|
Great Boulder Resources Ltd
AU:GBR
|
$68.44 Million |
|
Epitomee Medical Ltd
TA:EPIT
|
$68.42 Million |
|
Daekyo
KO:019680
|
$68.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chunghwa Chemical Synthesis & Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,350,235,000 to 3,356,940,000, a change of 6,705,000 (0.2%).
- Net income of 53,032,000 contributed positively to equity growth.
- Dividend payments of 62,048,000 reduced retained earnings.
- Other comprehensive income increased equity by 26,483,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$53.03 Million | +1.58% |
| Dividends Paid | NT$62.05 Million | -1.85% |
| Other Comprehensive Income | NT$26.48 Million | +0.79% |
| Other Changes | NT$-10.76 Million | -0.32% |
| Total Change | NT$- | 0.20% |
Book Value vs Market Value Analysis
This analysis compares Chunghwa Chemical Synthesis & Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.64x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.67x to 0.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$16.90 | NT$28.25 | x |
| 2010-12-31 | NT$22.32 | NT$28.25 | x |
| 2011-12-31 | NT$20.52 | NT$28.25 | x |
| 2012-12-31 | NT$21.50 | NT$28.25 | x |
| 2013-12-31 | NT$21.21 | NT$28.25 | x |
| 2014-12-31 | NT$20.20 | NT$28.25 | x |
| 2015-12-31 | NT$23.55 | NT$28.25 | x |
| 2016-12-31 | NT$22.70 | NT$28.25 | x |
| 2017-12-31 | NT$23.28 | NT$28.25 | x |
| 2018-12-31 | NT$25.32 | NT$28.25 | x |
| 2019-12-31 | NT$25.76 | NT$28.25 | x |
| 2020-12-31 | NT$31.90 | NT$28.25 | x |
| 2021-12-31 | NT$36.95 | NT$28.25 | x |
| 2022-12-31 | NT$40.67 | NT$28.25 | x |
| 2023-12-31 | NT$42.90 | NT$28.25 | x |
| 2024-12-31 | NT$44.04 | NT$28.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chunghwa Chemical Synthesis & Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.94%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.42x
- Recent ROE (1.58%) is below the historical average (10.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 15.13% | 14.39% | 0.37x | 2.81x | NT$41.53 Million |
| 2009 | 21.05% | 21.75% | 0.49x | 1.99x | NT$128.66 Million |
| 2010 | 11.69% | 15.62% | 0.51x | 1.48x | NT$27.09 Million |
| 2011 | 10.70% | 14.24% | 0.51x | 1.49x | NT$11.15 Million |
| 2012 | 10.48% | 13.20% | 0.44x | 1.80x | NT$8.01 Million |
| 2013 | 5.86% | 9.28% | 0.34x | 1.84x | NT$-68.29 Million |
| 2014 | 0.93% | 1.54% | 0.30x | 2.04x | NT$-142.52 Million |
| 2015 | 16.80% | 26.53% | 0.40x | 1.56x | NT$124.78 Million |
| 2016 | 3.40% | 5.03% | 0.44x | 1.54x | NT$-116.80 Million |
| 2017 | 4.71% | 7.34% | 0.34x | 1.89x | NT$-96.32 Million |
| 2018 | 11.81% | 22.98% | 0.32x | 1.62x | NT$35.89 Million |
| 2019 | 5.81% | 10.12% | 0.34x | 1.71x | NT$-84.49 Million |
| 2020 | 21.29% | 34.46% | 0.49x | 1.26x | NT$282.03 Million |
| 2021 | 13.85% | 20.72% | 0.44x | 1.51x | NT$111.37 Million |
| 2022 | 14.59% | 22.00% | 0.46x | 1.43x | NT$146.58 Million |
| 2023 | 7.91% | 12.70% | 0.40x | 1.54x | NT$-70.11 Million |
| 2024 | 1.58% | 3.94% | 0.28x | 1.42x | NT$-282.66 Million |
Industry Comparison
This section compares Chunghwa Chemical Synthesis & Biotech Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,607,751,556
- Average return on equity (ROE) among peers: 3.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | NT$3.21 Billion | 15.13% | 0.38x | $68.46 Million |
| Apex Biotechnology Corp (1733) | $1.35 Billion | 29.84% | 0.15x | $89.90 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.42 Billion | 0.26% | 0.72x | $188.76 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $184.23 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $99.61 Million |
| Level Biotechnology (3118) | $522.28 Million | 13.08% | 0.40x | $34.35 Million |
| GenMont Biotech Inc (3164) | $290.14 Million | -2.84% | 0.08x | $47.96 Million |
| Medigen Biotechnology (3176) | $3.54 Billion | -16.06% | 0.36x | $144.62 Million |
| Sagittarius Life Science (3205) | $965.47 Million | -11.83% | 0.10x | $119.60 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $98.37 Million |
About Chunghwa Chemical Synthesis & Biotech Co Ltd
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DM… Read more